Loading...
Please wait, while we are loading the content...
Similar Documents
Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination.
| Content Provider | Europe PMC |
|---|---|
| Author | Zaloum, Safiya A Wood, Callum H Tank, Pooja Upcott, Matthew Vickaryous, Nicola Anderson, Valerie Baker, David Chance, Randy Evangelou, Nikos George, Katila Giovannoni, Gavin Harding, Katharine E Hibbert, Aimee Ingram, Gillian Jolles, Stephen Kang, Angray S Loveless, Samantha Moat, Stuart J Richards, Aidan Robertson, Neil P Rios, Francesca Schmierer, Klaus Willis, Mark Dobson, Ruth Tallantyre, Emma C |
| Copyright Year | 2023 |
| Abstract | Background:People with multiple sclerosis (pwMS) treated with certain disease-modifying therapies (DMTs) have attenuated IgG response following COVID-19 vaccination; however, the clinical consequences remain unclear.Objective:To report COVID-19 rates in pwMS according to vaccine serology.Methods:PwMS with available (1) serology 2–12 weeks following COVID-19 vaccine 2 and/or vaccine 3 and (2) clinical data on COVID-19 infection/hospitalisation were included. Logistic regression was performed to examine whether seroconversion following vaccination predicted risk of subsequent COVID-19 infection after adjusting for potential confounders. Rates of severe COVID-19 (requiring hospitalisation) were also calculated.Results:A total of 647 pwMS were included (mean age 48 years, 500 (77%) female, median Expanded Disability Status Scale (EDSS) 3.5% and 524 (81%) exposed to DMT at the time of vaccine 1). Overall, 472 out of 588 (73%) were seropositive after vaccines 1 and 2 and 222 out of 305 (73%) after vaccine 3. Seronegative status after vaccine 2 was associated with significantly higher odds of subsequent COVID-19 infection (odds ratio (OR): 2.35, 95% confidence interval (CI): 1.34–4.12, p = 0.0029), whereas seronegative status after vaccine 3 was not (OR: 1.05, 95% CI: 0.57–1.91). Five people (0.8%) experienced severe COVID-19, all of whom were seronegative after most recent vaccination.Conclusion:Attenuated humoral response to initial COVID-19 vaccination predicts increased risk of COVID-19 in pwMS, but overall low rates of severe COVID-19 were seen. |
| Related Links | https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC10333979&blobtype=pdf |
| ISSN | 13524585 |
| Journal | Multiple Sclerosis (Houndmills, Basingstoke, England) [Mult Scler] |
| Volume Number | 29 |
| DOI | 10.1177/13524585231185247 |
| PubMed Central reference number | PMC10333979 |
| Issue Number | 8 |
| PubMed reference number | 37431627 |
| e-ISSN | 14770970 |
| Language | English |
| Publisher | SAGE Publications |
| Publisher Date | 2023-07-01 |
| Publisher Place | Sage UK: London, England |
| Access Restriction | Open |
| Rights License | This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections. © The Author(s), 2023 |
| Subject Keyword | Multiple sclerosis (MS) COVID-19 vaccination disease-modifying therapies (DMTs) immune response |
| Content Type | Text |
| Resource Type | Article |
| Subject | Neurology Neurology (clinical) |
